Key result
Ticagrelor, ruciromab, and PGE1, but not ASA, suppressed platelet coagulation activity by decreasing phosphatidylserine exposure and reducing the rate of plasma clotting and thrombin generation.
Why the study?
To investigate the effects of antiplatelet drugs on platelet impact in fibrin formation, thrombin generation, and phosphatidylserine exposure.
Do antiplatelet drugs (ASA, ticagrelor, ruciromab, PGE1) reduce platelet-dependent coagulation reactions and phosphatidylserine exposure in human platelets?
Do antiplatelet drugs (ASA, ticagrelor, ruciromab, PGE1) reduce platelet-dependent coagulation reactions and phosphatidylserine exposure in human platelets?
Ticagrelor, ruciromab, and PGE1, but not aspirin alone, suppress platelet-dependent coagulation activity and phosphatidylserine exposure both in vitro and in patients with ACS.
No takes yet. Share an insight, caveat, or question.
Supports further investigation of differential platelet effects; should not yet change clinical antiplatelet practice.
Muravlev et al. (2023) studied Acute coronary syndrome. Antiplatelet drugs (Ticagrelor, ASA, ruciromab, PGE1) vs. No medication / ASA alone was evaluated on Fibrin formation, thrombin generation, and phosphatidylserine exposure. Ticagrelor, ruciromab, and PGE1, but not ASA, suppressed platelet coagulation activity by decreasing phosphatidylserine exposure and reducing the rate of plasma clotting and thrombin generation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: